|
|
Abbott Laboratories (ABT) |
|
|
|
| |
ABT's Operating Income Growth by Quarter and Year
Abbott Laboratories's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| ABT Operating Income (in millions $) |
FY 2021 |
FY 2020 |
FY 2019 |
FY 2018 |
| IV Quarter |
December |
-
|
2,432.00
|
1,389.00
|
1,165.00
|
| III Quarter |
September |
-
|
1,495.00
|
1,198.00
|
995.00
|
| II Quarter |
June |
-
|
672.00
|
1,206.00
|
882.00
|
| I Quarter |
March |
2,109.00
|
758.00
|
739.00
|
608.00
|
| FY |
|
2,109.00
|
5,357.00
|
4,532.00
|
3,650.00
|
| ABT Operating Income first quarter 2021 Y/Y Growth Comment |
Abbott Laboratories achieved in the first quarter, above Company average Operating Income surge of 178.23% year on year, to $ 2,109.00 millions.
Looking into first quarter results within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Operating Income growth. While Abbott Laboratories' s Operating Income doubling of 178.23% ranks overall at the positon no. 306 in the first quarter.
Explain Operating Income growth
|
| ABT Operating Income ( Y/Y Growth %) |
2021
|
2020 |
2019 |
2018 |
| IV Quarter |
December |
- |
75.09 % |
19.23 % |
68.6 % |
| III Quarter |
September |
- |
24.79 % |
20.4 % |
22.84 % |
| II Quarter |
June |
- |
-44.28 % |
36.73 % |
106.56 % |
| I Quarter |
March |
178.23 % |
2.57 % |
21.55 % |
- |
| FY |
|
- |
18.2 % |
24.16 % |
111.47 % |
ABT Operating Income (Quarter on Quarter Growth %) |
2021
|
2020 |
2019 |
2018 |
| IV Quarter |
December |
- |
62.68 % |
15.94 % |
17.09 % |
| III Quarter |
September |
- |
122.47 % |
-0.66 % |
12.81 % |
| II Quarter |
June |
- |
-11.35 % |
63.19 % |
45.07 % |
| I Quarter |
March |
-13.28 % |
-45.43 % |
-36.57 % |
-12.01 % |
| FY (Year on Year) |
|
- |
18.2 % |
24.16 % |
111.47 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 64.74 % |
1.12 % |
-54.93 % |
| (Dec. 31. 2007) |
|
(Sep. 30, 2015) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 64.74 % |
1.12 % |
-54.93 % |
| (Dec. 31. 2007) |
|
(Sep. 30, 2015) |
|
| Operating Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021 |
Abbott Laboratories's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 313.29 % |
14 % |
-75.54 % |
| (June 30. 2012) |
|
|
| ABT's I. Quarter Q/Q Operating Income Comment |
In the I. Quarter 2021 Abbott Laboratories disclosed drop in Operating Income sequentially by -13.28% to $ 2,109.00 millions, from $ 2,432.00 millions declared in the previous reporting period.
It's not important concern, as Operating Income always tend to plunge in this quarter Isaac Thompson, an industry consultant told.
Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Operating Income quarter on quarter growth. While Abbott Laboratories's Operating Income growth quarter on quarter, overall rank is 829. |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 313.29 % |
14 % |
-75.54 % |
| (June 30. 2012) |
|
|
| ABT's I. Quarter Q/Q Operating Income Comment |
In the I. Quarter 2021 Abbott Laboratories realized drop in Operating Income from the previous quarter by -13.28% to $ 2,109.00 millions, from $ 2,432.00 millions released in the previous quarter.
This is not big issue, as I. Quarter Operating Income generally seem to dip in this quarter Isaac Thompson, an industry consultant noted.
Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Operating Income quarter on quarter growth. While Abbott Laboratories's Operating Income growth quarter on quarter, overall rank is 829. |
|
Abbott Laboratories's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Mar 31 2021) |
12 Months Ending
(Dec 31 2020) |
12 Months Ending
(Sep 30 2020) |
12 Months Ending
(Jun 30 2020) |
12 Months Ending
(Mar 31 2020) |
| Cumulative Operating Income 12 Months Ending |
$ 6,708.00 |
$ 5,357.00 |
$ 4,314.00 |
$ 4,017.00 |
$ 4,551.00 |
| Y / Y Operating Income Growth (TTM) |
47.4 % |
18.2 % |
0.14 % |
-2.14 % |
20.36 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 225 |
# 223 |
# 714 |
# 918 |
# 534 |
| Seqeuential Operating Income Change (TTM) |
25.22 % |
24.18 % |
7.39 % |
-11.73 % |
0.42 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 306 |
# 483 |
# 802 |
# 1492 |
# 179 |
| Cumulative Operating Income growth
Comment |
Abbott Laboratories saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 47.4% year on year, to $ 6,708 millions if the fiscal year would have ended in Mar 31 2021.
Abbott Laboratories's trailing twelve months Operating Income growth was higher than company's average 9.94% and higher than 18.2% growth in Dec 31 2020.
But from twelve months ended Dec 31 2020 rise was slower at 25.22 % from $5357 millions reported in twelve months ending a quarter Dec 31 2020.
Yet it was evidence of strength, as the typical Q/Q TTM Operating Income advancement lays at 1.12%.
The momentum was much higher from the previous reporting period exhibited at 25.22 % increase from $5357 millions in twelve months ending a quarter before.
Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 223 to 225. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
64.74 % |
1.12 % |
-54.93 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
157.45 % |
9.94 % |
-65.4 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 6 |
| Sector |
# 19 |
| S&P 500 |
# 306 |
|
| Cumulative Operating Income growth
Comment |
Abbott Laboratories saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 47.4% year on year, to $ 6,708 millions if the fiscal year would have ended in Mar 31 2021.
Abbott Laboratories's trailing twelve months Operating Income growth was higher than company's average 9.94% and higher than 18.2% growth in Dec 31 2020.
But from twelve months ended Dec 31 2020 rise was beneth at 25.22 % from $5357 millions achieved in twelve months ending a quarter Dec 31 2020 Isaac Thompson continued.
In spite of, it was validation of convincing trend, while the average sequential growth is at 1.12%.
The progress was much higher from twelve months ended Dec 31 2020 exhibited at 25.22 % rise from $5357 millions in the period from Dec 31 2020 to Mar 31 2020.
Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 223 to 225. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
64.74 % |
1.12 % |
-54.93 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
157.45 % |
9.94 % |
-65.4 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 6 |
| Sector |
# 19 |
| S&P 500 |
# 306 |
|
277.14%